This invention relates to an expandable tubular stent for implantation in the lumen of a body duct in order to ensure a passage therein.
Such stents are used mainly in the treatment of blood vessels exhibiting stenoses, and more generally in the treatment of diseases of various anatomical ducts of the human or animal body, such as, for example, the urinary ducts, especially the urethra, or the digestive ducts, especially the esophagus.
The percutaneous implantation of an expandable tubular stent in a stenotic blood vessel is generally recommended, for example after a conventional angioplasty procedure, for preventing the dilated vessel from closing up again spontaneously or for preventing its occlusion by the formation of a new atheromatous plaque and the possible recurrence of stenosis.
A known type of expandable tubular stent consists of an assembly of radially expandable, tubular elements aligned along a common longitudinal axis and successively joined together in pairs by respective sets of linking members. Such a stent is disclosed, for example, in international patent application WO 98/58600 in which each of the tubular elements consists of a strip forming a zigzag corrugation defining bent extreme portions which are successively connected together in pairs in opposite directions by rectilinear intermediate portions. By virtue of this zigzag corrugation, the stent is expandable between a first, unexpanded state, enabling it to be implanted percutaneously by means of an insertion device of reduced diameter, and a second, expanded state, in which the stent makes it possible to ensure a passage in the lumen of the body duct. Stents of this type are also disclosed in international patent applications WO 96/26689 and WO 98/20810.
To install the stent, it is placed in the unexpanded state on an angioplasty balloon catheter. Once in place, the balloon is inflated in order to cause the stent to expand. Alternatively, the stent may be made from a material which has a recovery capacity, so that the stent may automatically expand, once in place.
According to the invention there is provided a stent comprising a tubular body made up of a plurality of separate, radially expandable, tubular elements aligned along a common longitudinal axis, wherein at least some of the tubular elements each comprise a plurality of closed cell elements, each joined to the next by a circumferentially-extending linking member.
It will thus be seen that each tubular element comprises a closed loop consisting of a series of alternating closed cell elements and circumferential linking members.
In most known stents, the tubular elements are physically linked to one another by longitudinally extending linking members. One or more of such longitudinally extending linking members may link each pair of adjacent tubular elements. However, there are a number of advantages to be obtained by not using longitudinally-extending linking members, so that the stent consists simply of a collection of separate tubular members whose alignment along a common axis to form the stent is achieved by other means. Preferably the tubular elements, as well as being expandable, are also compressible.
By “separate” is meant that the tubular elements are not directly connected together by longitudinally-extending linking members. The word “separate” does not imply that the elements may not touch and, as will be explained below, in certain conditions of the stent, the linking members will touch and will indeed link together. In the absence of longitudinally-extending linking members, the structural integrity of the stent is realised by alternative means, such as:
1) A tubular member or framework which is not directly joined to the adjacent tubular elements but over which or within which the tubular elements are positioned in the desired alignment. For example, the balloon which is used to expand the stent can be used to maintain the position of the tubular members with respect to one another.
2) Interlock means which mechanically holds the tubular members together even though they are not directly joined. An example of this would be to provide co-operating interlock means on the tubular elements themselves.
In an embodiment of the invention, both these techniques are employed: the tubular elements are placed over the balloon and interlocked together so that the stent remains structurally stable during its often tortuous passage to the treatment site. Upon expansion, the interlocking is released, and the balloon alone then maintains the positional stability of the stent components. After the balloon has been deflated, the expanded stent, which has undergone plastic deformation, maintains its expanded shape and thus keeps the vessel being treated at its desired diameter. The expanded vessel applies a reaction force, due to its elastic nature, against the stent and thus maintains the position of the individual tubular elements making up the stent with respect to one another.
In order to allow the stent to expand it is necessary that the tubular elements be radially expandable. For this purpose, each tubular element is constructed in such a way that it is expandable in the circumferential direction. This may be achieved by the closed cell construction of the invention in which the expansion capabilities of the tubular elements are contained wholly or primarily in the closed cell elements. To avoid out of balance forces during expansion, it is preferred that the closed cell elements be positioned symmetrically with respect to the circumferential linking members, but asymmetric arrangements are also possible.
The tubular elements making up the stent may be all identical, or they may be different—for example, a stent could be made up of a combination of tubular elements comprising closed cell elements, and tubular elements constructed in some other way, arranged to create particular desired properties of the stent as a whole.
The circumferential linking members may simply consist of rectilinear members extending in the circumferential direction. Alternatively the circumferential linking members may be angled to the circumferential direction, so long as they have a component in the circumferential direction so that the adjacent closed cell elements are spaced apart in the circumferential direction. In a further alternative, the circumferential linking members are not rectilinear, but are some other shape to create particular desired characteristics—for example, the circumferential linking members could be such as to provide a degree of flexibility in the circumferential direction, although the expansion capabilities of the tubular element will still be primarily due to the closed cell elements. Preferably, all of the circumferential linking members are the same length in the circumferential direction so that the closed cell elements are evenly distributed about the circumference of the tubular element.
The circumferential linking members attach to the closed cell elements at respective spaced attachment points, and each closed cell element is constructed in such a way that it is capable of expanding from a first position in which the attachment points are relatively close together to a second position in which the attachment points are relatively further apart. In this way, the circumferential length of the tubular element can be increased from a relatively low value, corresponding to the unexpanded condition of the stent, to a relatively higher value, corresponding to the expanded condition of the stent. In one possible construction, each closed cell element comprises two individual members extending between said attachment points, said members being spaced apart in the direction of the longitudinal axis of the stent. Thus, one of said members may be said to be the proximal member, the other the distal member. The proximal and distal members are preferably symmetrically arranged about a straight line joining the two attachment points, this line being coaxial around the circumference with the general direction of the circumferential linking members.
The proximal and distal members are capable of bending in order to enable the expansion of the closed cell element from the first position to the second position. This may be achieved in various ways. For example, each of the proximal and distal members may be fabricated from a flexible member which is thus able to bend to accommodate the required movement. Alternatively, each of the proximal and distal members is fabricated by a plurality of relatively rigid side members joined by hinge members. In the preferred embodiment, each of the proximal and distal members comprises two such side members joined together by a hinge. Preferably the two side members are of equal length, but they do not need to be; however, for a symmetric construction the corresponding side members in each of the proximal and distal members should be of equal length.
In an embodiment, each closed cell element has a generally rhombic or diamond shape, comprising four side members of relatively stiff construction, joined by four hinge members corresponding to the corners of the rhombus. The circumferential linking members attach to the closed cell element at the location of opposite hinge members. Thus, each circumferential linking member has, at one end, one of the hinge members of one closed cell element and, at the opposite end, the opposite hinge member of the adjacent closed cell element.
It is not essential that all the closed cell elements in each tubular element are the same shape. In an alternative embodiment every other closed cell element is of rhombic shape, as described above, whilst the closed cell elements in between comprise “double rhombic” elements, each comprising two rhombic shapes, as described above, aligned in the circumferential direction, but joined by a narrow, but not closed, neck portion.
Other arrangements of closed cell elements are possible, according to the circumstances.
The aforesaid interlock means can conveniently be provided by providing an enlarged portion at each of the hinge members to which the link members are not attached. The narrowing side members as they approach each hinge member, together with the respective enlarged portion, form a narrow or waist portion which can overlap with an enlarged portion from the next adjacent tubular element. Two such waist portions acting together can thus retain an enlarged portion from the next adjacent tubular element.
The interlock means do not have to be provided on every closed cell element. It may be adequate to provide them on just a few closed cell elements, but evenly spaced about the circumference, so as to give a balanced attachment between adjacent tubular elements. For this purpose some of the closed cell elements may extend further in the axial direction of the stent than the remaining closed cell elements, so that these extended portions may interlink with the adjacent tubular element.
This enlarged portion can be formed as a flexible open cell with a narrowed neck, or can be formed as a relatively rigid block, from which, for example, the two side members may emerge via a respective narrowed portion to act as a hinge—in this latter case, the hinge member actually consists of two separate hinges.
In current medical practice, it is often the case that, in addition to its role in providing ongoing support for the vessel wall, the stent is required to act as a means whereby therapeutic agents may conveniently be applied. Indeed the trauma caused during the angioplasty procedure may call for localised drug treatment. In addition, drugs may be used to counteract restenosis, and for other purposes. Conventionally, such therapeutic agents are contained within some form of coating which is applied to the stent so that the drug will be released over a period of time. One problem with such an arrangement, however, is that, whereas the drug needs primarily to be applied through the wall of the vessel being treated, in practice as much of the drug is released into the fluid, e.g. blood, flowing within the vessel as passes through the vessel wall. Not only is the drug which is washed away effectively wasted, it can also do positive harm elsewhere if, for example, it enters a sensitive organ such as the heart.
Thus, in an embodiment of the invention the stent is equipped with wells opening into its exterior surface—that surface which, when the stent is in place, will face the wall of the vessel being treated—said wells being suitable to contain therapeutic agent.
The wells may comprise holes or grooves opening into the exterior surface of the stent, and may or may not pass right through the material of the stent to the interior of the stent. However, if the wells pass through to the interior of the stent there is clearly a danger of at least some of the drug being released into the fluid flowing within the vessel. Therefore it is preferred that, in such a case, that end of the well which opens into the interior of the stent is constructed, for example by being made narrower, and/or being plugged by a material which prevents or considerably reduces the tendency of the therapeutic agent to flow therethrough.
Thus it is preferred that the well is wholly or primarily open to the exterior surface of the stent so that the therapeutic agent may act directly on the wall of the vessel and does not get washed away by the fluid flowing along the vessel being treated.
The wells may open onto any suitable exterior surface of the stent. For example, the wells may conveniently be formed in the blocks which form the enlarged portions of the closed cell elements. For example, each block could be formed with a well in the form of a hole, which may or may not be a through hole and which opens into that surface of the block which forms part of the exterior surface of the stent. Alternatively the wells may be formed as grooves in the side members of the closed cell elements, the grooves opening into that surface of the side members which forms part of the exterior surface of the stent. It will be understood, however, that the above positions are given just as examples.
As mentioned above, the wells contain therapeutic agents which are intended to be released at a controlled rate against the wall of the vessel being treated. Not all of the wells necessarily will contain the therapeutic agent, and not all wells need to contain the same therapeutic agent. It is possible, for example, that the wells of different tubular elements contain different therapeutic agent, opening up the possibility of providing mixtures of drugs by choosing particular tubular elements carrying particular drugs to make up the stent. Clearly this is particularly easy with a stent in which the tubular elements are separate from one another. The therapeutic agents may also be provided in separate layers within the well, with the drug needed first being in the top layer, and the drugs needed later in lower layers, in correct sequence.
In addition, it is possible to provide that some of the wells contain therapeutic agents which have different rates of release. For example the drug contained in the wells of those tubular elements at or near the ends of the stent could be arranged to have a more rapid or a slower release rate than the remainder.
The therapeutic agents may be provided in any suitable form for retention in the wells, and for sustained release, once installed within the vessel. Examples are liquid, gel or powder form.
In order that the invention may be better understood, several embodiments thereof will now be described by way of example only and with reference to the accompanying drawings in which:
Referring firstly to
It will be noted that the tubular elements 1 are separate from one another in the sense that there is no direct physical link between them, keeping the tubular elements 1 in position. Instead alternative means are used to maintain the structural integrity of the stent. This will be explained in more detail below.
In the stent illustrated, all of the tubular elements are identical in structure and size although, as mentioned above, this need not necessarily be the case. A single tubular element 1 is shown, in two dimensional form in
A single closed cell element 2 is shown in enlarged detail in
The hinge members 21, 23 are formed by narrowed sections 28, 29 where the respective side members 24/27, 25/26 join the respective linking member 3. The hinge members 20, 22 are formed as a loop 30 having a narrowed opening 31 into the interior 32 of the cell element. This narrowed opening 31 corresponds to a waisted portion 33 which cooperates in the interlocking of individual tubular elements 1, as will be explained below.
Before the stent is used, it will generally be crimped to the balloon which will carry it to the treatment site and subsequently expand it. The crimping process involves compressing the “as cut” stent onto the balloon so that it is securely gripped. During compression the diameter of the tubular elements, decreases and this is achieved by a deformation of the closed cell elements 2 in such a way as to tend to close the elements up—i.e. so that the hinge members 21 and 23 move towards one another, thus reducing the circumferential length of the tubular element 1. During this process the closed cell elements bend at the hinge members 20 to 23. The crimped condition of the stent is illustrated in
It will be noted in
When the stent reaches the treatment site, and the physician is satisfied as to its correct position, the balloon carrying the stent is expanded, in the known manner, to expand the stent from its condition shown in
It will also be noted that, during expansion, the length, in the longitudinal direction of the stent, of each of the closed cell elements 2 reduces and this effect, in a stent with linking members between adjacent tubular elements, causes the overall length of the stent to reduce. This reduction in length is undesirable for various reasons, and it will be seen that the use of independent tubular elements 1 substantially eliminates this problem.
The stents of
The difference between the embodiments of
The advantages of a stent with independent tubular elements over one in which the tubular elements are linked by linking members can be summarised as follows:
1) Manufacture is made easier because only a basic tubular element has to be cut. Any stent length can readily be created by adding the appropriate number of tubular elements at the commencement of the assembly or crimping process.
2) The crimped stent has a high degree of longitudinal flexibility since it is not restrained by the inter-element linking members of known stents.
3) The crimped stent has a high degree of longitudinal conformability due to its tubular elements being interlocked at multiple cell locations.
4) There is substantially no shortening of the stent during expansion because the shortening of each tubular element does not affect the stent as a whole.
5) Once deployed, the stent has a high degree of longitudinal flexibility and of longitudinal and radial conformability due to the absence of the restraint imposed by inter-element linking members.
6) Once deployed the stent has a good vessel repartition and vessel scaffolding, with homogeneous support for the vessel wall—see particularly
Thus, any therapeutic agent contained within the wells 35 acts directly on the wall of the vessel, and is not substantially affected by the flow of fluid within the vessel.
Although only a single well 35 is formed in each block 34, it is possible for multiple smaller wells to be formed, perhaps each containing different drugs. Different drugs can be supplied on different tubular elements, making it easy to create a stent, as needed, containing an appropriate recipe of drugs.
The holes making up the wells 35 can be formed as through-holes, and plugged from the interior side to create a blind hole. Alternatively, the through hole can be left, and a suitable substance which will resist the washing away of the drug contained within the well can be deposited at the inner end of the through hole.
Although the wells 35 are shown as circular holes, it will be understood that other shapes are possible, including multi-sided, square or rectangular. Alternatively, the wells can be formed as grooves or slots opening into the exterior surface of the block 34.
The wells may additionally or instead of be provided at other locations, such as on the side members 24 to 27 of the closed cell elements 2. However, for this purpose, the side members would have to be made less deformable than they might otherwise be since any deformation of the reservoir during stent crimping or deployment might result in delamination of the reservoir contents, which would be undesirable. The blocks 34 are seen as attractive since they suffer substantially less deformation than other parts of the stent because their bulk, relative to the remaining components of the stent, is such that they are relatively stiff.
In the embodiment shown in
The enlarged view of
In the embodiment of
On the right hand side a block 41 is formed outside of the loop 30 and, once again, is equipped with a well 35 in the form of a blind hole. Since there is room beyond the hinge members 20, 22, the block 41 does not interfere with the interlocking of the tubular element 1 together during crimping, as described above.
The advantages of stents incorporating wells, as described above, can be summarised as follows:
1) The well can hold drugs without the need for a polymer matrix coating. The use of wells can eliminate coating delamination during stent deployment, thus reducing the risk of thrombosis.
2) The absence of a polymer matrix coating eliminates any potential biocompatibility problems arising from their use.
3) Once the stent is fully deployed, the outside surface of the stent is pushed against the wall of the vessel being treated; this means that the well is open only towards the vessel wall, to enable diffusion of the drugs into the vessel wall. In addition, the drug cannot be washed out by the flow of fluid in the vessel and so cannot have undesired effects elsewhere.
4) Compared to a thin (0.1-5 micron) drug layer coated on the stent, the reservoir can be loaded with a high dose and long life time.
5) The reservoir dimensions (diameter, length, width, depth) can be readily varied to the particular circumstances such as blood flow direction and drug release kinetics.
6) Each well can contain a single drug and therefore different drugs can be individually held in different wells without the danger of their reacting with each other.
Referring to
In both embodiments, the closed cell elements between the elements 50 are of different shape to the elements 50. These elements, given the reference 53, each comprise two rhombic-shaped sections 54, 55 which are joined by a narrow open neck portion 57.
The joining of adjacent tubular elements is shown in
The aperture 56 formed within the loop 30 in the embodiment of
The stent which has been described is expandable between an unexpanded state (in practice, probably the crimped condition mentioned 10 above), in which it is able to be guided inside the lumen through a body duct, such as a blood vessel, for example, and an expanded state, in which the stent, after a uniform expansion, comes into contact with the inner wall of the body duct, defining a passage of approximately constant diameter inside said duct.
The stent will generally be forcibly expanded mechanically under the action of a force exerted radially outwards, for example under the effect of the inflation of a balloon. However, the stent may be of the “auto-expandable” type, i.e. capable of changing by itself from a first, unexpanded condition under stress, enabling it to be guided through the body duct, to a second, expanded, working condition.
The stent may be made of any material compatible with the body duct and the body fluids with which it may come into contact.
In the case of an auto-expandable stent, it will be preferable to use a material with a recovery capacity, for example, stainless steel, Phynox® or nitinol.
In the case of a stent utilising a forced expansion, a material with a low elastic recovery capacity may be used to advantage. Examples are metallic materials such as tungsten, platinum, tantalum, gold, or stainless steel.
The tubular elements 1 may be manufactured from a hollow tube with an approximately constant thickness corresponding to the desired thickness. The shape of the tubular elements may be formed either by laser cutting followed by electrochemical polishing, or by chemical or electrochemical treatment.
The tubular elements may alternatively be manufactured from a sheet of approximately constant thickness corresponding to the desired thickness of the stent. The geometric configuration of the tubular elements can be obtained either by laser cutting followed by electrochemical polishing, or by chemical or electrochemical treatment. The sheet cut in this way is then rolled up to form a cylinder and welded to give the desired final structure.
After assembly of the tubular elements 1 into a stent of the desired length, the stent can be deployed in a manner known per se. In the case of a stent utilising mechanically forced expansion, the insertion system will preferably comprise a balloon catheter onto which the stent will be crimped 15 in the unexpanded state before being introduced into an insertion tube for guiding it to the site to be treated.
The stent of the invention can be intended for both temporary or permanent placement in the duct or vessel to be treated.
| Number | Date | Country | Kind |
|---|---|---|---|
| 0121980.7 | Sep 2001 | GB | national |
| 02252698 | Apr 2002 | EP | regional |
The present application is a continuation of U.S. patent application Ser. No. 10/489,181 filed Mar. 10, 2004, now abandoned, which is a National Stage Entry of PCT Application No. PCT/EP02/09931, filed Sep. 5, 2002, which claims priority to both European Patent Application No. 02252698.2, filed Apr. 16, 2002, and British Patent Application No. 0121980.7, filed Sep. 11, 2001. The entire contents of each of the above patent applications is fully incorporated herein by reference.
| Number | Name | Date | Kind |
|---|---|---|---|
| 4069825 | Akiyama | Jan 1978 | A |
| 4468224 | Enzmann et al. | Aug 1984 | A |
| 4512338 | Balko | Apr 1985 | A |
| 4564014 | Fogarty et al. | Jan 1986 | A |
| 4580568 | Gianturco | Apr 1986 | A |
| 4681110 | Wiktor | Jul 1987 | A |
| 4690684 | McGreevy et al. | Sep 1987 | A |
| 4733665 | Palmaz | Mar 1988 | A |
| 4739762 | Palmaz | Apr 1988 | A |
| 4748982 | Horzewski et al. | Jun 1988 | A |
| 4762129 | Bonzel | Aug 1988 | A |
| 4770176 | McGreevy et al. | Sep 1988 | A |
| 4775337 | Van Wagener et al. | Oct 1988 | A |
| 4776337 | Palmaz | Oct 1988 | A |
| 4886062 | Wiktor | Dec 1989 | A |
| 4891225 | Langer et al. | Jan 1990 | A |
| 4988356 | Crittenden et al. | Jan 1991 | A |
| 4994066 | Voss | Feb 1991 | A |
| 4994069 | Ritchart et al. | Feb 1991 | A |
| 5013318 | Spranza, III | May 1991 | A |
| 5035706 | Giantureo et al. | Jul 1991 | A |
| 5040548 | Yock | Aug 1991 | A |
| 5061273 | Yock | Oct 1991 | A |
| 5064435 | Porter | Nov 1991 | A |
| 5092877 | Pinchuk | Mar 1992 | A |
| 5102417 | Palmaz | Apr 1992 | A |
| 5104404 | Wolff | Apr 1992 | A |
| 5122154 | Rhodes | Jun 1992 | A |
| 5135535 | Kramer | Aug 1992 | A |
| 5192297 | Hull | Mar 1993 | A |
| 5195984 | Schatz | Mar 1993 | A |
| 5201757 | Heyn et al. | Apr 1993 | A |
| 5217495 | Kaplan et al. | Jun 1993 | A |
| 5219355 | Parodi et al. | Jun 1993 | A |
| 5226913 | Pinchuk | Jul 1993 | A |
| 5246421 | Saab | Sep 1993 | A |
| 5273536 | Savas | Dec 1993 | A |
| 5282824 | Gianturco | Feb 1994 | A |
| 5300085 | Yock | Apr 1994 | A |
| 5312415 | Palermo | May 1994 | A |
| 5334187 | Fischell et al. | Aug 1994 | A |
| 5391172 | Williams et al. | Feb 1995 | A |
| 5421955 | Lau et al. | Jun 1995 | A |
| 5445646 | Euteneuer et al. | Aug 1995 | A |
| 5456713 | Chuter | Oct 1995 | A |
| 5458615 | Klemm et al. | Oct 1995 | A |
| 5470315 | Adams | Nov 1995 | A |
| 5478349 | Nicholas | Dec 1995 | A |
| 5484444 | Braunschweiler et al. | Jan 1996 | A |
| 5490837 | Blaeser et al. | Feb 1996 | A |
| 5496346 | Horzewski et al. | Mar 1996 | A |
| 5501227 | Yock | Mar 1996 | A |
| 5507768 | Lau et al. | Apr 1996 | A |
| 5507771 | Gianturco | Apr 1996 | A |
| 5514093 | Ellis et al. | May 1996 | A |
| 5514154 | Lau et al. | May 1996 | A |
| 5527354 | Fontaine et al. | Jun 1996 | A |
| 5531735 | Thompson | Jul 1996 | A |
| 5534007 | St. Germain et al. | Jul 1996 | A |
| 5549551 | Peacock, III et al. | Aug 1996 | A |
| 5549563 | Kronner | Aug 1996 | A |
| 5549635 | Solar | Aug 1996 | A |
| 5554181 | Das | Sep 1996 | A |
| 5562725 | Schmitt et al. | Oct 1996 | A |
| 5571086 | Kaplan et al. | Nov 1996 | A |
| 5593412 | Martinez et al. | Jan 1997 | A |
| 5607444 | Lam | Mar 1997 | A |
| 5607463 | Schwartz et al. | Mar 1997 | A |
| 5628775 | Jackson et al. | May 1997 | A |
| 5634928 | Fischell et al. | Jun 1997 | A |
| 5639274 | Fischell et al. | Jun 1997 | A |
| 5662675 | Polanskyj Stockert et al. | Sep 1997 | A |
| 5670161 | Healy et al. | Sep 1997 | A |
| 5676654 | Ellis et al. | Oct 1997 | A |
| 5683451 | Lenker et al. | Nov 1997 | A |
| 5690644 | Yurek et al. | Nov 1997 | A |
| 5693085 | Buirge et al. | Dec 1997 | A |
| 5697948 | Marin et al. | Dec 1997 | A |
| 5697971 | Fischell et al. | Dec 1997 | A |
| 5702418 | Ravenscroft | Dec 1997 | A |
| 5709701 | Parodi | Jan 1998 | A |
| 5716393 | Lindenberg et al. | Feb 1998 | A |
| 5722669 | Shimizu et al. | Mar 1998 | A |
| 5723003 | Winston et al. | Mar 1998 | A |
| 5735869 | Fernandez-Aceytuno | Apr 1998 | A |
| 5741323 | Pathak et al. | Apr 1998 | A |
| 5749848 | Jang et al. | May 1998 | A |
| 5749921 | Lenker et al. | May 1998 | A |
| 5755772 | Evans et al. | May 1998 | A |
| 5755776 | Al-Saadon | May 1998 | A |
| 5755781 | Jayaraman | May 1998 | A |
| 5769882 | Fogarty et al. | Jun 1998 | A |
| 5772669 | Vrba | Jun 1998 | A |
| 5776141 | Klein et al. | Jul 1998 | A |
| 5797951 | Mueller et al. | Aug 1998 | A |
| 5800519 | Sandock | Sep 1998 | A |
| 5807398 | Shaknovich | Sep 1998 | A |
| 5824040 | Cox et al. | Oct 1998 | A |
| 5824041 | Lenker et al. | Oct 1998 | A |
| 5833694 | Poncet | Nov 1998 | A |
| 5836964 | Richter et al. | Nov 1998 | A |
| 5843092 | Heller et al. | Dec 1998 | A |
| 5855563 | Kaplan et al. | Jan 1999 | A |
| 5858556 | Eckert et al. | Jan 1999 | A |
| 5870381 | Kawasaki et al. | Feb 1999 | A |
| 5879370 | Fischell et al. | Mar 1999 | A |
| 5891190 | Boneau | Apr 1999 | A |
| 5895398 | Wensel et al. | Apr 1999 | A |
| 5899935 | Ding | May 1999 | A |
| 5902332 | Schatz | May 1999 | A |
| 5919175 | Sirhan | Jul 1999 | A |
| 5921971 | Agro et al. | Jul 1999 | A |
| 5922020 | Klein et al. | Jul 1999 | A |
| 5941869 | Patterson et al. | Aug 1999 | A |
| 5951585 | Cathcart et al. | Sep 1999 | A |
| 5961536 | Mickley et al. | Oct 1999 | A |
| 5968069 | Dusbabek et al. | Oct 1999 | A |
| 5972027 | Johnson | Oct 1999 | A |
| 5976107 | Mertens et al. | Nov 1999 | A |
| 5976155 | Foreman et al. | Nov 1999 | A |
| 5980484 | Ressemann et al. | Nov 1999 | A |
| 5980486 | Enger | Nov 1999 | A |
| 5980514 | Kupiecki et al. | Nov 1999 | A |
| 5980552 | Pinchasik et al. | Nov 1999 | A |
| 5984957 | Laptewicz, Jr. et al. | Nov 1999 | A |
| 5997563 | Kretzers et al. | Dec 1999 | A |
| 6004328 | Solar | Dec 1999 | A |
| 6007517 | Anderson | Dec 1999 | A |
| 6022359 | Frantzen | Feb 2000 | A |
| 6022374 | Imran | Feb 2000 | A |
| 6033434 | Borghi | Mar 2000 | A |
| 6036725 | Avellanet | Mar 2000 | A |
| 6039721 | Johnson et al. | Mar 2000 | A |
| 6042589 | Marianne | Mar 2000 | A |
| 6056722 | Jayaraman | May 2000 | A |
| 6063111 | Hieshima et al. | May 2000 | A |
| 6066155 | Amann et al. | May 2000 | A |
| 6068655 | Seguin et al. | May 2000 | A |
| 6070589 | Keith et al. | Jun 2000 | A |
| 6090063 | Makower et al. | Jul 2000 | A |
| 6090136 | McDonald et al. | Jul 2000 | A |
| 6102942 | Ahari | Aug 2000 | A |
| 6106530 | Harada | Aug 2000 | A |
| RE36857 | Euteneuer et al. | Sep 2000 | E |
| 6120522 | Vrba et al. | Sep 2000 | A |
| 6123712 | Di Caprio et al. | Sep 2000 | A |
| 6123723 | Konya et al. | Sep 2000 | A |
| 6126685 | Lenker et al. | Oct 2000 | A |
| 6129756 | Kugler | Oct 2000 | A |
| 6132460 | Thompson | Oct 2000 | A |
| 6139572 | Campbell et al. | Oct 2000 | A |
| 6143016 | Bleam et al. | Nov 2000 | A |
| 6165167 | Delaloye | Dec 2000 | A |
| 6165210 | Lau et al. | Dec 2000 | A |
| 6171334 | Cox | Jan 2001 | B1 |
| 6179878 | Duerig | Jan 2001 | B1 |
| 6183509 | Dibie | Feb 2001 | B1 |
| 6187034 | Frantzen | Feb 2001 | B1 |
| 6190402 | Horton et al. | Feb 2001 | B1 |
| 6196995 | Fagan | Mar 2001 | B1 |
| 6200337 | Moriuchi et al. | Mar 2001 | B1 |
| 6238991 | Suzuki | May 2001 | B1 |
| 6241691 | Ferrera et al. | Jun 2001 | B1 |
| 6241758 | Cox | Jun 2001 | B1 |
| 6248122 | Klumb et al. | Jun 2001 | B1 |
| 6251132 | Ravenscroft et al. | Jun 2001 | B1 |
| 6251134 | Alt et al. | Jun 2001 | B1 |
| 6254612 | Hieshima | Jul 2001 | B1 |
| 6254628 | Wallace et al. | Jul 2001 | B1 |
| 6258117 | Camrud et al. | Jul 2001 | B1 |
| 6264688 | Herklotz et al. | Jul 2001 | B1 |
| 6267783 | Letendre et al. | Jul 2001 | B1 |
| 6270524 | Kim | Aug 2001 | B1 |
| 6273895 | Pinchuk et al. | Aug 2001 | B1 |
| 6273911 | Cox et al. | Aug 2001 | B1 |
| 6273913 | Wright et al. | Aug 2001 | B1 |
| 6287291 | Bigus et al. | Sep 2001 | B1 |
| 6312458 | Golds | Nov 2001 | B1 |
| 6315794 | Richter | Nov 2001 | B1 |
| 6319277 | Rudnick et al. | Nov 2001 | B1 |
| 6322586 | Monroe et al. | Nov 2001 | B1 |
| 6325823 | Horzewski et al. | Dec 2001 | B1 |
| 6334871 | Dor et al. | Jan 2002 | B1 |
| 6340366 | Wijay | Jan 2002 | B2 |
| 6344272 | Oldenburg et al. | Feb 2002 | B1 |
| 6348065 | Brown et al. | Feb 2002 | B1 |
| 6350277 | Kocur | Feb 2002 | B1 |
| 6357104 | Myers | Mar 2002 | B1 |
| 6361558 | Hieshima et al. | Mar 2002 | B1 |
| 6375676 | Cox | Apr 2002 | B1 |
| 6379365 | Diaz | Apr 2002 | B1 |
| 6383171 | Gifford et al. | May 2002 | B1 |
| 6409753 | Brown et al. | Jun 2002 | B1 |
| 6415696 | Erickeson et al. | Jul 2002 | B1 |
| 6416543 | Hilaire et al. | Jul 2002 | B1 |
| 6419693 | Fariabi | Jul 2002 | B1 |
| 6425898 | Wilson et al. | Jul 2002 | B1 |
| 6428811 | West et al. | Aug 2002 | B1 |
| 6451025 | Jervis | Sep 2002 | B1 |
| 6451050 | Rudakov et al. | Sep 2002 | B1 |
| 6464720 | Boatman et al. | Oct 2002 | B2 |
| 6468298 | Pelton | Oct 2002 | B1 |
| 6468299 | Stack et al. | Oct 2002 | B2 |
| 6485510 | Camrud et al. | Nov 2002 | B1 |
| 6488694 | Lau et al. | Dec 2002 | B1 |
| 6488702 | Besselink | Dec 2002 | B1 |
| 6511468 | Cragg et al. | Jan 2003 | B1 |
| 6520986 | Martin et al. | Feb 2003 | B2 |
| 6520987 | Plante | Feb 2003 | B1 |
| 6527789 | Lau et al. | Mar 2003 | B1 |
| 6527799 | Shanley | Mar 2003 | B2 |
| 6530944 | West et al. | Mar 2003 | B2 |
| 6540777 | Stenzel | Apr 2003 | B2 |
| 6551350 | Thornton et al. | Apr 2003 | B1 |
| 6555157 | Hossainy | Apr 2003 | B1 |
| 6562067 | Mathis | May 2003 | B2 |
| 6569180 | Sirhan et al. | May 2003 | B1 |
| 6575993 | Yock | Jun 2003 | B1 |
| 6579305 | Lashinski | Jun 2003 | B1 |
| 6579309 | Loos et al. | Jun 2003 | B1 |
| 6582394 | Reiss et al. | Jun 2003 | B1 |
| 6582460 | Cryer | Jun 2003 | B1 |
| 6585756 | Strecker | Jul 2003 | B1 |
| 6592549 | Gerdts et al. | Jul 2003 | B2 |
| 6599296 | Gillick et al. | Jul 2003 | B1 |
| 6599314 | Mathis | Jul 2003 | B2 |
| 6602226 | Smith et al. | Aug 2003 | B1 |
| 6602282 | Yan | Aug 2003 | B1 |
| 6605062 | Hurley et al. | Aug 2003 | B1 |
| 6605109 | Fiedler | Aug 2003 | B2 |
| 6607553 | Healy et al. | Aug 2003 | B1 |
| 6629992 | Bigus et al. | Oct 2003 | B2 |
| 6645517 | West | Nov 2003 | B2 |
| 6645547 | Shekalim et al. | Nov 2003 | B1 |
| 6656212 | Ravenscroft et al. | Dec 2003 | B2 |
| 6660031 | Tran et al. | Dec 2003 | B2 |
| 6660381 | Halas et al. | Dec 2003 | B2 |
| 6663660 | Dusbabek et al. | Dec 2003 | B2 |
| 6666883 | Seguin et al. | Dec 2003 | B1 |
| 6676693 | Belding et al. | Jan 2004 | B1 |
| 6676695 | Solem | Jan 2004 | B2 |
| 6679909 | McIntosh et al. | Jan 2004 | B2 |
| 6685730 | West et al. | Feb 2004 | B2 |
| 6692465 | Kramer | Feb 2004 | B2 |
| 6699280 | Camrud et al. | Mar 2004 | B2 |
| 6699281 | Vallana et al. | Mar 2004 | B2 |
| 6699724 | West et al. | Mar 2004 | B1 |
| 6702843 | Brown | Mar 2004 | B1 |
| 6709379 | Brandau et al. | Mar 2004 | B1 |
| 6709440 | Callol et al. | Mar 2004 | B2 |
| 6712827 | Ellis et al. | Mar 2004 | B2 |
| 6712845 | Hossainy | Mar 2004 | B2 |
| 6723071 | Gerdts et al. | Apr 2004 | B2 |
| 6736842 | Healy et al. | May 2004 | B2 |
| 6743219 | Dwyer et al. | Jun 2004 | B1 |
| 6743251 | Eder | Jun 2004 | B1 |
| 6761734 | Suhr | Jul 2004 | B2 |
| 6778316 | Halas et al. | Aug 2004 | B2 |
| 6800065 | Duane et al. | Oct 2004 | B2 |
| 6825203 | Pasternak et al. | Nov 2004 | B2 |
| 6837901 | Rabkin et al. | Jan 2005 | B2 |
| 6849084 | Rabkin et al. | Feb 2005 | B2 |
| 6852252 | Halas et al. | Feb 2005 | B2 |
| 6855125 | Shanley | Feb 2005 | B2 |
| 6858034 | Hijlkema et al. | Feb 2005 | B1 |
| 6878161 | Lenker | Apr 2005 | B2 |
| 6884257 | Cox | Apr 2005 | B1 |
| 6893417 | Gribbons et al. | May 2005 | B2 |
| 6896695 | Mueller et al. | May 2005 | B2 |
| 6913619 | Brown et al. | Jul 2005 | B2 |
| 6918928 | Wolinsky et al. | Jul 2005 | B2 |
| 6939376 | Shulz et al. | Sep 2005 | B2 |
| 6945989 | Betelia et al. | Sep 2005 | B1 |
| 6945995 | Nicholas | Sep 2005 | B2 |
| 6951053 | Padilla et al. | Oct 2005 | B2 |
| 6962603 | Brown et al. | Nov 2005 | B1 |
| 6964676 | Gerberding et al. | Nov 2005 | B1 |
| 6991646 | Clerc et al. | Jan 2006 | B2 |
| 6994721 | Israel | Feb 2006 | B2 |
| 7005454 | Brocchini et al. | Feb 2006 | B2 |
| 7022132 | Kocur | Apr 2006 | B2 |
| 7037327 | Salmon et al. | May 2006 | B2 |
| 7090694 | Morris et al. | Aug 2006 | B1 |
| 7101840 | Brocchini et al. | Sep 2006 | B2 |
| 7137993 | Acosta et al. | Nov 2006 | B2 |
| 7141063 | White et al. | Nov 2006 | B2 |
| 7147655 | Chermoni | Dec 2006 | B2 |
| 7147656 | Andreas et al. | Dec 2006 | B2 |
| 7169172 | Levine et al. | Jan 2007 | B2 |
| 7175654 | Bonsignore et al. | Feb 2007 | B2 |
| 7182779 | Acosta et al. | Feb 2007 | B2 |
| 7192440 | Andreas et al. | Mar 2007 | B2 |
| 7208001 | Coyle et al. | Apr 2007 | B2 |
| 7220755 | Betts et al. | May 2007 | B2 |
| 7238197 | Sequin et al. | Jul 2007 | B2 |
| 7241308 | Andreas et al. | Jul 2007 | B2 |
| 7244336 | Fischer et al. | Jul 2007 | B2 |
| 7270668 | Andreas et al. | Sep 2007 | B2 |
| 7294146 | Chew et al. | Nov 2007 | B2 |
| 7300456 | Andreas et al. | Nov 2007 | B2 |
| 7309350 | Landreville et al. | Dec 2007 | B2 |
| 7314480 | Eidenschink et al. | Jan 2008 | B2 |
| 7320702 | Hammersmark et al. | Jan 2008 | B2 |
| 7323006 | Andreas et al. | Jan 2008 | B2 |
| 7326236 | Andreas et al. | Feb 2008 | B2 |
| 7351255 | Andreas | Apr 2008 | B2 |
| 7534449 | Saltzman et al. | May 2009 | B2 |
| 8016870 | Chew et al. | Sep 2011 | B2 |
| 20010020154 | Bigus et al. | Sep 2001 | A1 |
| 20010020173 | Klumb et al. | Sep 2001 | A1 |
| 20010020181 | Layne | Sep 2001 | A1 |
| 20010035902 | Iddan et al. | Nov 2001 | A1 |
| 20010044595 | Reydel et al. | Nov 2001 | A1 |
| 20010044632 | Daniel et al. | Nov 2001 | A1 |
| 20010049547 | Moore | Dec 2001 | A1 |
| 20020037358 | Barry et al. | Mar 2002 | A1 |
| 20020052642 | Cox et al. | May 2002 | A1 |
| 20020091439 | Baker et al. | Jul 2002 | A1 |
| 20020092536 | LaFontaine et al. | Jul 2002 | A1 |
| 20020107560 | Richter | Aug 2002 | A1 |
| 20020111671 | Stenzel | Aug 2002 | A1 |
| 20020123786 | Gittings et al. | Sep 2002 | A1 |
| 20020128706 | Osypka | Sep 2002 | A1 |
| 20020138132 | Brown | Sep 2002 | A1 |
| 20020151924 | Shiber | Oct 2002 | A1 |
| 20020151955 | Tran et al. | Oct 2002 | A1 |
| 20020156496 | Chermoni | Oct 2002 | A1 |
| 20020168317 | Daighighian et al. | Nov 2002 | A1 |
| 20020177890 | Lenker | Nov 2002 | A1 |
| 20020183763 | Callol et al. | Dec 2002 | A1 |
| 20020188343 | Mathis | Dec 2002 | A1 |
| 20020188347 | Mathis | Dec 2002 | A1 |
| 20020193873 | Brucker et al. | Dec 2002 | A1 |
| 20030045923 | Bashiri | Mar 2003 | A1 |
| 20030093143 | Zhao et al. | May 2003 | A1 |
| 20030097169 | Brucker et al. | May 2003 | A1 |
| 20030114912 | Sequin et al. | Jun 2003 | A1 |
| 20030114919 | McQuiston et al. | Jun 2003 | A1 |
| 20030114922 | Iwasaka et al. | Jun 2003 | A1 |
| 20030125791 | Sequin et al. | Jul 2003 | A1 |
| 20030125800 | Shulze et al. | Jul 2003 | A1 |
| 20030125802 | Callol et al. | Jul 2003 | A1 |
| 20030135259 | Simso | Jul 2003 | A1 |
| 20030135266 | Chew et al. | Jul 2003 | A1 |
| 20030139796 | Sequin et al. | Jul 2003 | A1 |
| 20030139797 | Johnson et al. | Jul 2003 | A1 |
| 20030139798 | Brown et al. | Jul 2003 | A1 |
| 20030163085 | Tanner et al. | Aug 2003 | A1 |
| 20030176909 | Kusleika | Sep 2003 | A1 |
| 20030191516 | Weldon et al. | Oct 2003 | A1 |
| 20030195609 | Berenstein | Oct 2003 | A1 |
| 20030199821 | Gerdts et al. | Oct 2003 | A1 |
| 20030204238 | Tedeschi | Oct 2003 | A1 |
| 20030208223 | Kleiner | Nov 2003 | A1 |
| 20030212447 | Euteneuer | Nov 2003 | A1 |
| 20030225446 | Hartley | Dec 2003 | A1 |
| 20040024450 | Shulze et al. | Feb 2004 | A1 |
| 20040030380 | Shulze et al. | Feb 2004 | A1 |
| 20040044395 | Nelson | Mar 2004 | A1 |
| 20040073290 | Chouinard | Apr 2004 | A1 |
| 20040093061 | Acosta et al. | May 2004 | A1 |
| 20040093067 | Israel | May 2004 | A1 |
| 20040106979 | Goicoechea | Jun 2004 | A1 |
| 20040111145 | Serino et al. | Jun 2004 | A1 |
| 20040117008 | Wnendt et al. | Jun 2004 | A1 |
| 20040143322 | Litvack et al. | Jul 2004 | A1 |
| 20040176832 | Hartley et al. | Sep 2004 | A1 |
| 20040181239 | Dorn et al. | Sep 2004 | A1 |
| 20040186551 | Kao et al. | Sep 2004 | A1 |
| 20040193245 | Deem et al. | Sep 2004 | A1 |
| 20040215312 | Andreas et al. | Oct 2004 | A1 |
| 20040230285 | Gifford, III et al. | Nov 2004 | A1 |
| 20040243217 | Andersen et al. | Dec 2004 | A1 |
| 20040249434 | Andreas et al. | Dec 2004 | A1 |
| 20050010276 | Acosta et al. | Jan 2005 | A1 |
| 20050038494 | Eidenschink | Feb 2005 | A1 |
| 20050038505 | Shulze et al. | Feb 2005 | A1 |
| 20050049673 | Andreas et al. | Mar 2005 | A1 |
| 20050080474 | Andreas et al. | Apr 2005 | A1 |
| 20050080475 | Andreas et al. | Apr 2005 | A1 |
| 20050085897 | Bonsignore | Apr 2005 | A1 |
| 20050090846 | Pedersen et al. | Apr 2005 | A1 |
| 20050125051 | Eidenschink et al. | Jun 2005 | A1 |
| 20050131008 | Betts et al. | Jun 2005 | A1 |
| 20050143827 | Globerman et al. | Jun 2005 | A1 |
| 20050165378 | Heinrich et al. | Jul 2005 | A1 |
| 20050209674 | Kutscher et al. | Sep 2005 | A1 |
| 20050222671 | Schaeffer et al. | Oct 2005 | A1 |
| 20050228477 | Grainger et al. | Oct 2005 | A1 |
| 20050245637 | Hossainy et al. | Nov 2005 | A1 |
| 20050288764 | Snow et al. | Dec 2005 | A1 |
| 20050288766 | Plain et al. | Dec 2005 | A1 |
| 20060069424 | Acosta et al. | Mar 2006 | A1 |
| 20060173529 | Blank | Aug 2006 | A1 |
| 20060200223 | Andreas et al. | Sep 2006 | A1 |
| 20060206190 | Chermoni | Sep 2006 | A1 |
| 20060229700 | Acosta et al. | Oct 2006 | A1 |
| 20060229706 | Shulze et al. | Oct 2006 | A1 |
| 20060271150 | Andreas et al. | Nov 2006 | A1 |
| 20060271151 | McGarry et al. | Nov 2006 | A1 |
| 20060282147 | Andreas et al. | Dec 2006 | A1 |
| 20060282149 | Kao | Dec 2006 | A1 |
| 20060282150 | Olson et al. | Dec 2006 | A1 |
| 20060287726 | Segal et al. | Dec 2006 | A1 |
| 20070027521 | Andreas et al. | Feb 2007 | A1 |
| 20070043419 | Nikolchev et al. | Feb 2007 | A1 |
| 20070067012 | George et al. | Mar 2007 | A1 |
| 20070088368 | Acosta et al. | Apr 2007 | A1 |
| 20070088420 | Andreas et al. | Apr 2007 | A1 |
| 20070088422 | Chew et al. | Apr 2007 | A1 |
| 20070100423 | Acosta et al. | May 2007 | A1 |
| 20070100424 | Chew et al. | May 2007 | A1 |
| 20070106365 | Andreas et al. | May 2007 | A1 |
| 20070118202 | Chermoni | May 2007 | A1 |
| 20070118203 | Chermoni | May 2007 | A1 |
| 20070118204 | Chermoni | May 2007 | A1 |
| 20070129733 | Will et al. | Jun 2007 | A1 |
| 20070135906 | Badylak et al. | Jun 2007 | A1 |
| 20070156225 | George et al. | Jul 2007 | A1 |
| 20070156226 | Chew et al. | Jul 2007 | A1 |
| 20070179587 | Acosta et al. | Aug 2007 | A1 |
| 20070219612 | Andreas et al. | Sep 2007 | A1 |
| 20070219613 | Kao et al. | Sep 2007 | A1 |
| 20070265637 | Andreas et al. | Nov 2007 | A1 |
| 20070270936 | Andreas et al. | Nov 2007 | A1 |
| 20070276461 | Andreas et al. | Nov 2007 | A1 |
| 20070281117 | Kaplan et al. | Dec 2007 | A1 |
| 20070292518 | Ludwig | Dec 2007 | A1 |
| 20080004690 | Robaina | Jan 2008 | A1 |
| 20080046067 | Toyokawa | Feb 2008 | A1 |
| 20080071345 | Hammersmark et al. | Mar 2008 | A1 |
| 20080077229 | Andreas et al. | Mar 2008 | A1 |
| 20080091257 | Andreas et al. | Apr 2008 | A1 |
| 20080097299 | Andreas et al. | Apr 2008 | A1 |
| 20080097574 | Andreas et al. | Apr 2008 | A1 |
| 20080125850 | Andreas et al. | May 2008 | A1 |
| 20080132989 | Snow et al. | Jun 2008 | A1 |
| 20080147162 | Andreas et al. | Jun 2008 | A1 |
| 20080177369 | Will et al. | Jul 2008 | A1 |
| 20080199510 | Ruane et al. | Aug 2008 | A1 |
| 20080208311 | Kao et al. | Aug 2008 | A1 |
| 20080208318 | Kao et al. | Aug 2008 | A1 |
| 20080234795 | Snow et al. | Sep 2008 | A1 |
| 20080234798 | Chew et al. | Sep 2008 | A1 |
| 20080234799 | Acosta et al. | Sep 2008 | A1 |
| 20080243225 | Satasiya et al. | Oct 2008 | A1 |
| 20080249607 | Webster et al. | Oct 2008 | A1 |
| 20080269865 | Snow et al. | Oct 2008 | A1 |
| 20090076584 | Mao et al. | Mar 2009 | A1 |
| 20090105686 | Snow et al. | Apr 2009 | A1 |
| 20090149863 | Andreas et al. | Jun 2009 | A1 |
| 20090228088 | Lowe | Sep 2009 | A1 |
| 20090234428 | Snow et al. | Sep 2009 | A1 |
| 20090264979 | Kao et al. | Oct 2009 | A1 |
| 20100004729 | Chew et al. | Jan 2010 | A1 |
| Number | Date | Country |
|---|---|---|
| 1 953 1659 | Mar 1997 | DE |
| 196 30 469 | Jan 1998 | DE |
| 199 50 756 | Aug 2000 | DE |
| 101 03 000 | Aug 2002 | DE |
| 0 203 945 | Dec 1986 | EP |
| 0 274 129 | Jul 1988 | EP |
| 0 282 143 | Sep 1988 | EP |
| 0 505 686 | Sep 1992 | EP |
| 0 533 960 | Mar 1993 | EP |
| 0 596 145 | May 1994 | EP |
| 0 714 640 | Jun 1996 | EP |
| 0 947 180 | Oct 1999 | EP |
| 1 258 230 | Nov 2002 | EP |
| 1 266 638 | Dec 2002 | EP |
| 1 277 449 | Jan 2003 | EP |
| 1 290 987 | Mar 2003 | EP |
| 1 318 765 | Jun 2003 | EP |
| 1 523 959 | Apr 2005 | EP |
| 1 523 960 | Apr 2005 | EP |
| 2277875 | Nov 1994 | GB |
| 03-133446 | Jun 1991 | JP |
| 10-503663 | Apr 1998 | JP |
| 10-295823 | Nov 1998 | JP |
| 2000-516486 | Dec 2000 | JP |
| 2001-190687 | Jul 2001 | JP |
| 2004-121343 | Apr 2004 | JP |
| WO 9526695 | Oct 1995 | WO |
| WO 9529647 | Nov 1995 | WO |
| WO 9626689 | Sep 1996 | WO |
| WO 9633677 | Oct 1996 | WO |
| WO 9639077 | Dec 1996 | WO |
| WO 9746174 | Dec 1997 | WO |
| WO 9748351 | Dec 1997 | WO |
| WO 9805270 | Feb 1998 | WO |
| WO 9820810 | May 1998 | WO |
| WO 9837833 | Sep 1998 | WO |
| WO 9858600 | Dec 1998 | WO |
| WO 9901087 | Jan 1999 | WO |
| WO 9965421 | Dec 1999 | WO |
| WO 0012832 | Mar 2000 | WO |
| WO 0015151 | Mar 2000 | WO |
| WO 0025841 | May 2000 | WO |
| WO 0032136 | Jun 2000 | WO |
| WO 0041649 | Jul 2000 | WO |
| WO 0050116 | Aug 2000 | WO |
| WO 0056237 | Sep 2000 | WO |
| WO 0062708 | Oct 2000 | WO |
| WO 0072780 | Dec 2000 | WO |
| WO 0170297 | Sep 2001 | WO |
| WO 0191918 | Dec 2001 | WO |
| WO 02085253 | Oct 2002 | WO |
| WO 02098326 | Dec 2002 | WO |
| WO 03022178 | Mar 2003 | WO |
| WO 03047651 | Jun 2003 | WO |
| WO 03051425 | Jun 2003 | WO |
| WO 03075797 | Sep 2003 | WO |
| WO 2004017865 | Mar 2004 | WO |
| WO 2004043299 | May 2004 | WO |
| WO 2004043301 | May 2004 | WO |
| WO 2004043510 | May 2004 | WO |
| WO 2004052237 | Jun 2004 | WO |
| WO 2005009295 | Feb 2005 | WO |
| WO 2005013853 | Feb 2005 | WO |
| WO 2006036939 | Apr 2006 | WO |
| WO 2006047520 | May 2006 | WO |
| WO 2007035805 | Mar 2007 | WO |
| WO 2007053187 | May 2007 | WO |
| WO 2007146411 | Dec 2007 | WO |
| WO 2008005111 | Jan 2008 | WO |
| Number | Date | Country | |
|---|---|---|---|
| 20090248137 A1 | Oct 2009 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 10489181 | US | |
| Child | 12481792 | US |